Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Eden Research ( (GB:EDEN) ) has shared an announcement.
Eden Research plc has signed an agreement with Véto-pharma to supply thymol, a bioactive molecule, for use in bee care products targeting varroa mite treatment in the US. This partnership is part of Eden’s strategy to diversify its revenue streams and enhance returns on investments in active ingredient dossiers across major markets, potentially leading to further collaboration opportunities.
More about Eden Research
Eden Research plc is a leader in sustainable biopesticide and biocontrol technology. The company focuses on developing and supplying bioactive compounds for use in various sectors, including pharmaceutical, agricultural, and consumer products, with a market focus on leveraging existing registrations and technologies to diversify its product portfolio.
YTD Price Performance: -34.18%
Average Trading Volume: 686,343
Technical Sentiment Signal: Strong Buy
Current Market Cap: £12.53M
See more insights into EDEN stock on TipRanks’ Stock Analysis page.